Equities analysts forecast that ABAXIS, Inc. (NASDAQ:ABAX) will report $0.24 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for ABAXIS’s earnings, with estimates ranging from $0.20 to $0.28. ABAXIS posted earnings per share of $0.30 during the same quarter last year, which would indicate a negative year over year growth rate of 20%. The firm is expected to issue its next earnings results on Thursday, January 25th.

According to Zacks, analysts expect that ABAXIS will report full year earnings of $1.10 per share for the current financial year, with EPS estimates ranging from $1.05 to $1.17. For the next fiscal year, analysts anticipate that the business will post earnings of $1.27 per share, with EPS estimates ranging from $1.20 to $1.39. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover ABAXIS.

ABAXIS (NASDAQ:ABAX) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. ABAXIS had a net margin of 11.98% and a return on equity of 10.18%. The business had revenue of $58.90 million during the quarter, compared to the consensus estimate of $60.85 million. During the same period last year, the business posted $0.34 EPS. ABAXIS’s revenue was up .5% on a year-over-year basis.

Several equities research analysts have issued reports on ABAX shares. TheStreet upgraded shares of ABAXIS from a “c+” rating to a “b-” rating in a research report on Wednesday. Zacks Investment Research upgraded shares of ABAXIS from a “sell” rating to a “hold” rating in a research report on Friday, November 10th. Canaccord Genuity reaffirmed a “hold” rating and set a $47.00 target price (up from $46.00) on shares of ABAXIS in a report on Friday, October 27th. Finally, Bank of America reaffirmed an “underperform” rating and set a $42.00 target price on shares of ABAXIS in a report on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $47.63.

Shares of ABAXIS (ABAX) opened at $48.14 on Friday. The stock has a market cap of $1,080.00, a P/E ratio of 40.62 and a beta of 0.86. ABAXIS has a 1 year low of $43.66 and a 1 year high of $55.95.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, December 1st will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 1.33%. This is a boost from ABAXIS’s previous quarterly dividend of $0.14. The ex-dividend date of this dividend is Thursday, November 30th. ABAXIS’s dividend payout ratio (DPR) is 53.33%.

ABAXIS declared that its Board of Directors has initiated a share repurchase plan on Tuesday, October 24th that permits the company to repurchase $21.00 million in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in ABAXIS by 61.4% in the second quarter. BNP Paribas Arbitrage SA now owns 7,349 shares of the medical research company’s stock valued at $390,000 after acquiring an additional 2,795 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in ABAXIS by 92.0% in the second quarter. UBS Asset Management Americas Inc. now owns 7,928 shares of the medical research company’s stock valued at $420,000 after acquiring an additional 3,799 shares during the last quarter. Vanguard Group Inc. increased its stake in ABAXIS by 0.9% in the second quarter. Vanguard Group Inc. now owns 1,963,755 shares of the medical research company’s stock valued at $104,119,000 after acquiring an additional 16,676 shares during the last quarter. Legal & General Group Plc grew its stake in shares of ABAXIS by 9.9% during the second quarter. Legal & General Group Plc now owns 44,532 shares of the medical research company’s stock worth $2,360,000 after buying an additional 4,017 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of ABAXIS by 5.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 100,590 shares of the medical research company’s stock worth $5,334,000 after buying an additional 4,963 shares during the last quarter. 97.51% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “$0.23 Earnings Per Share Expected for ABAXIS, Inc. (ABAX) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/02/0-23-earnings-per-share-expected-for-abaxis-inc-abax-this-quarter.html.

ABAXIS Company Profile

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Get a free copy of the Zacks research report on ABAXIS (ABAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABAXIS (NASDAQ:ABAX)

Receive News & Ratings for ABAXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABAXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.